摘要
目的比较两种不用方案治疗重度COPD(慢性阻塞性肺疾病)急性加重期细菌感染的疗效。方法将124例重度慢性阻塞性肺疾病急性加重期细菌感染患者按照治疗方案分成舒巴坦钠/头孢哌酮钠治疗组(A组)和他唑巴坦钠/哌拉西林钠治疗组(B组),治疗7 d后,比较两组的疗效,并通过药物经济学方法对成本-效果进行分析。结果 A组和B组的疗效分别为81.23%和76.98%(P>0.05),细菌清除率分别是78.12%和73.26%(P>0.05),治疗所需成本分别为(2010.23±175.5)和(2989.65±176.4)元,P<0.05。结论对于重度COPD急性加重期细菌感染的治疗,舒巴坦钠/头孢哌酮钠较他唑巴坦钠/哌拉西林钠更经济,值得推广。
Objective Compare the two without the treatment of moderate to severe COPD （chronic obstructive pulmonary disease） with acute exacerbation of bacterial infection efficacy. Method The 124 patients with severe chronic obstructive pulmonary disease in the treatment in aecordance with the treatment plan acute exacerbations of patients with bacterial infection is divided into group （A） of sulbactam sodium / eefoperazone sodium and group （B） of tazobactam sodium / piperacillin sodium in the treatment, after 7 days＇ treat- ment, the two groups were compared the efficacy and analysis the pharmaeoeconomics cost-effectiveness. Result The efficacy of the group A and group B, respectively, 81.23% and 76. 98% （ P 〉 0. 05 ）, The bacterial eradication rates were 78. 12% and 73.26% （ P 〉 0.05 ） , The treatment costs of （2010. 23 ± 175.5 ） and （2989.65 ± 176. 4）, P 〈 0. 05. Conclusion For severe acute exacerbation of COPD treatment of bacterial infections, sulbaetam sodium / cefoperazone sodium is more economical than tazobaetam sodium / piperacillin sodium worth promoting.
出处
《临床肺科杂志》
2013年第11期2017-2019,共3页
Journal of Clinical Pulmonary Medicine
